0001209191-22-039324.txt : 20220624 0001209191-22-039324.hdr.sgml : 20220624 20220624184353 ACCESSION NUMBER: 0001209191-22-039324 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220622 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Colowick Alan CENTRAL INDEX KEY: 0001316163 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38800 FILM NUMBER: 221041273 MAIL ADDRESS: STREET 1: C/O THRESHOLD PHARMACEUTICALS, INC. STREET 2: 1300 SEAPORT BOULEVARD, 5TH FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc. CENTRAL INDEX KEY: 0001708493 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473458693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-7400 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-22 0 0001708493 Harpoon Therapeutics, Inc. HARP 0001316163 Colowick Alan C/O HARPOON THERAPEUTICS, INC. 131 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Director Stock Option (Right to Buy) 2.01 2022-06-22 4 A 0 10167 0.00 A 2032-06-21 Common Stock 10167 10167 D Director Stock Option (Right to Buy) 2.01 2022-06-22 4 A 0 28571 1.40 A 2032-06-21 Common Stock 28571 28571 D The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $40,000 ("Election Option"). One-half of the Election Option vested and became exercisable on June 22, 2022, and 25% of each Election Option will vest and become exercisable on each of September 30, 2022 and December 31, 2022, subject to the continuous service of the Reporting Person with the Issuer through each vesting date. /s/ Alan Colowick by Georgia Erbez, Attorney-in-Fact 2022-06-24